CRISPR Therapeutics AG (CRSP) concluded trading on Thursady at a closing price of $86.19, with 4.28 million shares of worth about $369.15 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 79.82% during that period and on Thursady the price saw a gain of about 4.59%. Currently the company’s common shares owned by public are about 80.04M shares, out of which, 79.85M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 25 times over the past 12 months. They bought 132,854 shares in 9 of the transactions. In 16 selling transactions, insiders dumped 114,276 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the stock later moved at a day high price of 91.10, or with a gain of 4.59%. Stock saw a price change of 9.05% in past 5 days and over the past one month there was a price change of 30.22%. Year-to-date (YTD), CRSP shares are showing a performance of 37.68% which increased to 69.37% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $37.55 but also hit the highest price of $90.18 during that period. The average intraday trading volume for CRISPR Therapeutics AG shares is 2.71 million. The stock is currently trading 22.99% above its 20-day simple moving average (SMA20), while that difference is up 31.02% for SMA50 and it goes to 50.16% higher than SMA200.
CRISPR Therapeutics AG (NASDAQ: CRSP) currently have 80.04M outstanding shares and institutions hold larger chunk of about 64.91% of that.
The stock has a current market capitalization of $7.18B and its 3Y-monthly beta is at 1.75. It has posted earnings per share of -$1.97 in the same period. It has Quick Ratio of 17.54 while making debt-to-equity ratio of 0.13. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRSP, volatility over the week remained 8.48% while standing at 6.39% over the month.
Analysts are in expectations that CRISPR Therapeutics AG (CRSP) stock would likely to be making an EPS of -$1.3 in the current quarter, while forecast for next quarter EPS is -$1.59 and it is -$4.2 for next year. For the current quarter EPS, analysts have given the company a lowest target -$2.07 which is $0.74 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.67 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -196.03% while it is estimated to increase by 29.43% in next year.
Coverage by TD Cowen stated CRISPR Therapeutics AG (CRSP) stock as an Underperform in their note to investors on December 11, 2023, suggesting a price target of $30 for the stock. On October 17, 2023, Cantor Fitzgerald Downgrade their recommendations, while on September 27, 2023, Mizuho Initiated their ratings for the stock with a price target of $82. Stock get a Buy rating from Citigroup on August 17, 2023.
